Psilocybin shows promise as a treatment for psychiatric illnesses, but its federal illegality in the U.S. complicates access and regulation despite state-level decriminalization efforts. This article reviews current legal regulation, standard of care, right to effective treatment, and the respectable minority doctrine. It discusses ethical issues including provider bias, patient-provider dynamics, informed consent, and equity and access that psychiatrists must consider as psilocybin access expands for research.
As direct-to-consumer ketamine prescriptions and psychedelic support expand via telehealth, some patients are using general-purpose chatbots as de facto therapists during unmonitored altered-state sessions. This convergence of psychedelic therapeutics and generative AI creates an unregulated frontier in mental health care. Current AI tools are not licensed professionals, lack consistent reliability, cannot provide emergency support, and their unpredictability combined with mind-altering drugs can precipitate harm. Traditional safeguards relying on trained humans for supportive mindset and environment are disrupted when AI replaces that role. Clinicians should recognize patients already experiment with AI in this way, often without disclosure, and should counsel about dangers, document safety discussions, and routinely ask about AI use as part of risk assessment.